File Download
There are no files associated with this item.
Supplementary
- Citations:
- Appears in Collections:
Conference Paper: Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy
Title | Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy |
---|---|
Authors | |
Keywords | Chemotherapy Quantitative PCR NPC EBER-1 Serum Response monitoring |
Issue Date | 2001 |
Citation | Annals of the New York Academy of Sciences, 2001, v. 945, p. 73-79 How to Cite? |
Abstract | Nineteen consecutive patients with metastatic or recurrent nasopharyngeal cancer (NPC) receiving combination chemotherapy were monitored for EBV DNA in their serum. EBV DNA (EBER-1) concentration in serum was measured before, during, and after chemotherapy. Thirteen patients had additional multiple prechemotherapy readings. There was a significant lead time from first detection of serum EBER-1 to clinical recurrence in 62% of patients by a mean of 17.4 weeks (range: 8-74.5 weeks; mean = 28.2 weeks if confined to the 8 patients with significant lead time). The median EBER-1 concentration was significantly higher in those with distant metastasis as compared to those with loco-regional recurrence only (17,468 vs. 684 pg/mL serum; p = 0.046, Mann-Whitney U test). Among the 13 patients who responded to chemotherapy, 4 exhibited clinical complete remission (CR) who were only found in the group with EBER-1 DNA drop to background level, while the magnitude of EBER-1 drop did not discriminate partial remission (PR) and stable disease (SD) patients clearly. Subsequent profile of EBER-1 DNA showed concordance with clinical course of either continuous remission or later progression. EBER-1 DNA in serum can become a useful adjunctive surrogate marker to monitor chemotherapeutic response in NPC patients with distant metastasis or advanced local recurrence. |
Persistent Identifier | http://hdl.handle.net/10722/251594 |
ISSN | 2023 Impact Factor: 4.1 2023 SCImago Journal Rankings: 1.416 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ngan, Roger K.C. | - |
dc.contributor.author | Lau, W. H. | - |
dc.contributor.author | Yip, Timothy T.C. | - |
dc.contributor.author | Cho, William C.S. | - |
dc.contributor.author | Cheng, W. W. | - |
dc.contributor.author | Lim, C. K.P. | - |
dc.contributor.author | Wan, K. K. | - |
dc.contributor.author | Chu, E. | - |
dc.contributor.author | Joab, I. | - |
dc.contributor.author | Grunewald, V. | - |
dc.contributor.author | Poon, Y. F. | - |
dc.contributor.author | Ho, H. C.John | - |
dc.date.accessioned | 2018-03-08T05:00:25Z | - |
dc.date.available | 2018-03-08T05:00:25Z | - |
dc.date.issued | 2001 | - |
dc.identifier.citation | Annals of the New York Academy of Sciences, 2001, v. 945, p. 73-79 | - |
dc.identifier.issn | 0077-8923 | - |
dc.identifier.uri | http://hdl.handle.net/10722/251594 | - |
dc.description.abstract | Nineteen consecutive patients with metastatic or recurrent nasopharyngeal cancer (NPC) receiving combination chemotherapy were monitored for EBV DNA in their serum. EBV DNA (EBER-1) concentration in serum was measured before, during, and after chemotherapy. Thirteen patients had additional multiple prechemotherapy readings. There was a significant lead time from first detection of serum EBER-1 to clinical recurrence in 62% of patients by a mean of 17.4 weeks (range: 8-74.5 weeks; mean = 28.2 weeks if confined to the 8 patients with significant lead time). The median EBER-1 concentration was significantly higher in those with distant metastasis as compared to those with loco-regional recurrence only (17,468 vs. 684 pg/mL serum; p = 0.046, Mann-Whitney U test). Among the 13 patients who responded to chemotherapy, 4 exhibited clinical complete remission (CR) who were only found in the group with EBER-1 DNA drop to background level, while the magnitude of EBER-1 drop did not discriminate partial remission (PR) and stable disease (SD) patients clearly. Subsequent profile of EBER-1 DNA showed concordance with clinical course of either continuous remission or later progression. EBER-1 DNA in serum can become a useful adjunctive surrogate marker to monitor chemotherapeutic response in NPC patients with distant metastasis or advanced local recurrence. | - |
dc.language | eng | - |
dc.relation.ispartof | Annals of the New York Academy of Sciences | - |
dc.subject | Chemotherapy | - |
dc.subject | Quantitative PCR | - |
dc.subject | NPC | - |
dc.subject | EBER-1 | - |
dc.subject | Serum | - |
dc.subject | Response monitoring | - |
dc.title | Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy | - |
dc.type | Conference_Paper | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.pmid | 11708497 | - |
dc.identifier.scopus | eid_2-s2.0-0034751510 | - |
dc.identifier.volume | 945 | - |
dc.identifier.spage | 73 | - |
dc.identifier.epage | 79 | - |
dc.identifier.issnl | 0077-8923 | - |